Free Trial

Wellington Management Group LLP Sells 478,935 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

ADMA Biologics logo with Medical background

Wellington Management Group LLP lowered its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 80.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 119,293 shares of the biotechnology company's stock after selling 478,935 shares during the quarter. Wellington Management Group LLP owned approximately 0.05% of ADMA Biologics worth $2,385,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in ADMA. Calamos Advisors LLC raised its stake in shares of ADMA Biologics by 8.3% in the second quarter. Calamos Advisors LLC now owns 603,003 shares of the biotechnology company's stock valued at $6,742,000 after acquiring an additional 46,405 shares during the last quarter. Bank of New York Mellon Corp raised its position in ADMA Biologics by 6.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 766,544 shares of the biotechnology company's stock valued at $8,570,000 after purchasing an additional 49,631 shares during the last quarter. Viewpoint Capital Management LLC boosted its stake in ADMA Biologics by 32.4% in the second quarter. Viewpoint Capital Management LLC now owns 20,416 shares of the biotechnology company's stock worth $228,000 after purchasing an additional 5,000 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of ADMA Biologics by 5.4% during the second quarter. Rhumbline Advisers now owns 310,539 shares of the biotechnology company's stock worth $3,472,000 after purchasing an additional 15,844 shares during the last quarter. Finally, Victory Capital Management Inc. increased its stake in shares of ADMA Biologics by 192.6% in the second quarter. Victory Capital Management Inc. now owns 84,046 shares of the biotechnology company's stock valued at $940,000 after buying an additional 55,322 shares in the last quarter. 75.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on ADMA shares. HC Wainwright increased their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th. Cantor Fitzgerald reissued an "overweight" rating and set a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. Finally, Raymond James raised their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a report on Friday, November 8th.

Read Our Latest Research Report on ADMA Biologics

ADMA Biologics Trading Down 0.5 %

ADMA stock traded down $0.09 during midday trading on Wednesday, reaching $18.54. The stock had a trading volume of 552,159 shares, compared to its average volume of 3,555,292. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a twelve month low of $4.06 and a twelve month high of $23.64. The firm has a market cap of $4.38 billion, a price-to-earnings ratio of 66.54 and a beta of 0.70. The business has a fifty day simple moving average of $18.95 and a two-hundred day simple moving average of $16.23.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. During the same period in the previous year, the firm posted $0.01 earnings per share. As a group, research analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Insider Activity

In other news, CFO Brad L. Tade sold 15,000 shares of the company's stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares of the company's stock, valued at $4,218,007.95. This represents a 7.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 3.70% of the stock is currently owned by company insiders.

About ADMA Biologics

(Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Recommended Stories

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Should you invest $1,000 in ADMA Biologics right now?

Before you consider ADMA Biologics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.

While ADMA Biologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?

Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?

AVGO is up 30% since earnings: could Broadcom be the next member of the Magnificent Seven? Can it sustain this momentum or is a pullback on the horizon?

Related Videos

Why Meta Is Still a Top Stock Pick for 2025
Meta Platforms Tops Most Upgraded Stocks List—Here’s What to Expect
Alphabet Gaining Momentum: Can It Reach $200 by December?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines